Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 C2 vs C3 CIBERSORT analysis results

From: Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications

Immune cells Tumorigenic effect in breast cancera P C2 vs C3 differential expression
B cells memory Pro-tumorigenic 0.0242 C2 > C3
B cells naïve No effect 0.0798 C2 ≈ C3
Dendritic cells activated Anti-tumorigenic 0.0177 C2 > C3
Dendritic cells resting Pro-tumorigenic 0.4011 C2 ≈ C3
Eosinophils Pro-tumorigenic 0.0243 C2 > C3
Macrophages M0 Pro-tumorigenic < 0.0001 C2 > C3
Macrophages M1 Anti-tumorigenic 0.0005 C2 < C3
Macrophages M2 Pro-tumorigenic < 0.0001 C2 > C3
Mast cells activated Pro-tumorigenic < 0.0001 C2 > C3
Mast cells resting Anti-tumorigenic 0.0414 C2 < C3
Monocytes Pro-tumorigenic 0.0169 C2 > C3
Neutrophils Pro-tumorigenic 0.4571 C2 ≈ C3
NK cells activated Anti-tumorigenic 0.5534 C2 ≈ C3
NK cells resting Pro-tumorigenic 0.3776 C2 ≈ C3
Plasma cells Anti-tumorigenic < 0.0001 C2 < C3
T cells CD4 memory activated Anti-tumorigenic < 0.0001 C2 < C3
T cells CD4 memory resting Pro-tumorigenic 0.0481 C2 > C3
T cells CD4 naive Anti-tumorigenic 0.2901 C2 ≈ C3
T cells CD8 Anti-tumorigenic 0.0001 C2 < C3
T cells follicular helper Anti-tumorigenic 0.2394 C2 ≈ C3
T cells gamma delta Anti-tumorigenic < 0.0001 C2 < C3
T cells regulatory Anti-tumorigenic 0.4372 C2 ≈ C3
  1. aBased on results from Gentles et al. [21] except for macrophages M1 [22]